New drug hopes to stop liver scarring in its tracks

NCT ID NCT06920043

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This phase 2 trial tests a drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by fatty liver disease (MASH). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to check safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: efimosfermin alfa (also called BOS-580)
What this could lead to: If successful, this could point toward a treatment to control MASH-related cirrhosis and prevent liver disease from worsening.
What could go wrong: This is a small, early-phase trial focused on safety, not on curing the disease. The drug may not show enough benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Chandler, Arizona, 85224, United States
GSK Investigational Site
RECRUITING

Mesa, Arizona, 85381, United States
GSK Investigational Site
RECRUITING

Tucson, Arizona, 85712, United States
GSK Investigational Site
RECRUITING

Fresno, California, 93720, United States
GSK Investigational Site
RECRUITING

Lancaster, California, 93534, United States
GSK Investigational Site
RECRUITING

Pasadena, California, 91105, United States
GSK Investigational Site
RECRUITING

Rialto, California, 92377, United States
GSK Investigational Site
RECRUITING

Santa Maria, California, 93458, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33156, United States
GSK Investigational Site
RECRUITING

Viera, Florida, 32940, United States
GSK Investigational Site
RECRUITING

Marietta, Georgia, 30060, United States
GSK Investigational Site
RECRUITING

Baltimore, Maryland, 21202, United States
GSK Investigational Site
RECRUITING

Kansas City, Missouri, 64131, United States
GSK Investigational Site
RECRUITING

New York, New York, 10029, United States
GSK Investigational Site
RECRUITING

Fayetteville, North Carolina, 28304, United States
GSK Investigational Site
RECRUITING

Wilson, North Carolina, 27612, United States
GSK Investigational Site
RECRUITING

Austin, Texas, 78745, United States
GSK Investigational Site
RECRUITING

Austin, Texas, 78757, United States
GSK Investigational Site
RECRUITING

Austin, Texas, 78757, United States
GSK Investigational Site
RECRUITING

Dallas, Texas, 75203, United States
GSK Investigational Site
RECRUITING

Georgetown, Texas, 78626, United States
GSK Investigational Site
RECRUITING

Houston, Texas, 77030, United States
GSK Investigational Site
RECRUITING

Houston, Texas, 77030, United States
GSK Investigational Site
RECRUITING

Houston, Texas, 77079, United States
GSK Investigational Site
RECRUITING

Pasadena, Texas, 77505, United States
GSK Investigational Site
RECRUITING

Pearland, Texas, 77584, United States
GSK Investigational Site
RECRUITING

San Antonio, Texas, 78215, United States
GSK Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
GSK Investigational Site
RECRUITING

Waco, Texas, 76710, United States
GSK Investigational Site
RECRUITING

Richmond, Virginia, 23249, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.